View Exam | PowerPak

1. What is the A1C goal for most non-pregnant adults according to the ADA 2016 guidelines?

A. Less than 6% B. Less than 6.5% C. Less than 7% D. Less than 7.5%

2. Which of the following patient factors may warrant using a less stringent A1C goal?

A. The patient is young B. The patient has a history of hypoglycemia C. The patient has a long life expectancy D. The patient is a female

3. Which of the following is considered first line pharmacotherapy for patients with type 2 diabetes according to both the ADA and AACE guidelines?

A. Glyburide B. Pioglitazone C. Liraglutide D. Metformin

4. How are the GLP-1 RAs ranked in the current treatment algorithms?

A. Superseded only by metformin in AACE guidelines; second line in ADA guidelines B. Superseded only by metformin in AACE guidelines; third line in ADA guidelines C. First line in both guidelines D. Not ranked in either guideline, but may still be useful for certain patients

5. How do GLP-1 RAs help regulate blood glucose?

A. Released from the gastrointestinal tract, they suppress insulin release and promote glucagon release B. Released from the gastrointestinal tract, they slow gastric emptying, promote insulin release, and suppress glucagon release C. Released from the pancreas, they slow gastric emptying and suppress glucagon release D. Released from the pancreas, they suppress insulin release and promote glucagon release

6. Which of the following would be an appropriate counseling point for a patient starting basal insulin therapy?

A. This medication may cause nausea, vomiting, and diarrhea B. This medication may cause weight loss C. This medication may cause weight gain and hypoglycemia D. This medication will help lower your post-prandial blood glucose

7. What are some advantages of using a fixed-dose basal/GLP-1 RA therapy?

A. Helps minimize/reduce weight gain B. Minimizes hypoglycemia C. Allows for tighter glycemic control (better A1c reduction) D. All of the above

8. Which of the following GLP-1 RAs showed a reduction in the risk of major adverse cardiovascular events?

A. Dulaglutide B. Lixisenatide C. Liraglutide D. Albiglutide

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. What is the A1C goal for most non-pregnant adults according to the ADA 2016 guidelines?

2. Which of the following patient factors may warrant using a less stringent A1C goal?

3. Which of the following is considered first line pharmacotherapy for patients with type 2 diabetes according to both the ADA and AACE guidelines?

4. How are the GLP-1 RAs ranked in the current treatment algorithms?

5. How do GLP-1 RAs help regulate blood glucose?

6. Which of the following would be an appropriate counseling point for a patient starting basal insulin therapy?

7. What are some advantages of using a fixed-dose basal/GLP-1 RA therapy?

8. Which of the following GLP-1 RAs showed a reduction in the risk of major adverse cardiovascular events?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. What is the A1C goal for most non-pregnant adults according to the ADA 2016 guidelines?

2. Which of the following patient factors may warrant using a less stringent A1C goal?

3. Which of the following is considered first line pharmacotherapy for patients with type 2 diabetes according to both the ADA and AACE guidelines?

4. How are the GLP-1 RAs ranked in the current treatment algorithms?

5. How do GLP-1 RAs help regulate blood glucose?

6. Which of the following would be an appropriate counseling point for a patient starting basal insulin therapy?

7. What are some advantages of using a fixed-dose basal/GLP-1 RA therapy?

8. Which of the following GLP-1 RAs showed a reduction in the risk of major adverse cardiovascular events?

« Return to Activity

Customers who Purchased
this Activity also Purchased